BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Saturday. The brokerage set a “sell” rating on the medical technology company’s stock.

Several other research analysts also recently commented on the stock. Ascendiant Capital Markets reduced their price target on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

BIOL stock opened at $0.01 on Friday. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94. The firm has a market cap of $267,256.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. The business’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.06.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.